Aptorum Group Ltd
Business
Aptorum Group Ltd is a Cayman Islands-incorporated clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for oncology and infectious diseases. The company's lead projects are ALS-4, a small-molecule antibiotic targeting bacterial virulence for methicillin-resistant Staphylococcus aureus infections, and SACT-1, a repurposed drug candidate for neuroblastoma. Aptorum operates through subsidiaries in Hong Kong, the British Virgin Islands, and Singapore, and intends to market approved products primarily in the United States, Canada, Europe, and the PRC.
Summary from 20-F filed 2026-03-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-1.36M |
| Total assets | $18.69M |
| Total liabilities | $4.90M |
| Stockholders' equity | $23.12M |
| Operating cash flow | $-1.84M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Aptorum Group Ltd's CIK number?
Aptorum Group Ltd's SEC CIK number is 0001734005 (1734005). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aptorum Group Ltd's SEC filings?
All of Aptorum Group Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.